CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Emcure Pharmaceuticals Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Emcure Pharmaceuticals Ltd
Plot P-II
IT-BT Park, M.I.D.C., Hinjawadi
Phone: +91 2035070033p:+91 2035070033 PUNE, 411057  India Ticker: EMCUREEMCURE
Business Summary
Emcure Pharmaceuticals Limited is an India-based pharmaceutical company, which is engaged in developing, manufacturing and globally marketing a range of pharmaceutical products across several major therapeutic areas. It offers a range of products and services under formulations, biologics and APIs. It operates across a wide scope of areas, including gynecological, cardiology, antivirals, vitamins, pain/analgesics, anti-neoplastic, diabetes, anti-infective, respiratory, CNS and nephrology. Its brands include OROFER (Gynecological), BEVON (Vitamins), ZOSTUM (Anti- infectives), Ferium (Gynecological), EXHEP (Cardiovascular), Maxtra (Respiratory) and Pause (Blood-Related). Its API products include S-Amlodipine, Dydrogesterone, Ferric Carboxymaltose, Ferrous Ascorbate and Eribulin. Its biologics business offers various products, including Elaxim (cardiology), Vintor (nephrology), Xgrast (anti-neoplastic) and Pegex (anti- neoplastic). It has developed two platforms: Mammalian and Microbial.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/20243/31/2024Yes--Yes-

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Non-Executive Chairman of the Board Berjis M.Desai 68 1/1/2024 4/3/1992
Chief Executive Officer, Managing Director, Executive Director Satish R.Mehta 73 1/1/2024
Chief Financial Officer Tajuddin S.Shaikh 4/16/2021 4/16/2021
9 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Tillomed Laboratories Ltd. 220 Butterfield Great Marlings Luton United Kingdom
Manx Healthcare Ltd. Unit 2 Bosworth Ave Tournament Fields Warwick United Kingdom
Avet Pharmaceuticals Inc. 21 Cotters Lane East Brunswick NJ United States
International Pharmaceuticals Generics, Ltd. 4-77 Auriga Drive Ottawa ON Canada

Business Names
Business Name
EMCURE
International Pharmaceuticals Generics, Ltd.
Manx Healthcare Ltd.
Marcan Pharmaceuticals, Inc.
TILLOMED LABORATORIES LIMITED
Tillomed Laboratories Ltd.

General Information
Number of Employees: 11,146 (As of 3/31/2024)
Outstanding Shares: 189,483,347 (As of 3/24/2025)
Shareholders: 49
Stock Exchange: NSE
Fax Number: +91 2039821444
Email Address: Corporate@emcure.co.in


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, April 8, 2025